Athyrium Capital Management

Athyrium Capital Management is a specialized asset management firm established in 2008, dedicated to investment opportunities in the global healthcare sector. The firm manages funds with over $4.6 billion in committed capital, investing across various asset classes, including public equity, private equity, fixed income, royalties, and other structured securities. Athyrium's investment focus encompasses biopharmaceuticals, medical devices, healthcare services, and healthcare information technology.

The firm's investment strategy targets commercial-stage companies with compelling products and differentiated services, seeking investments ranging from $25 million to $150 million per transaction, with the flexibility to scale up opportunistically. Athyrium partners with management teams to implement creative financing solutions, aiming to achieve growth objectives and enhance value. The firm has a global investment mandate, with a presence in North America, Europe, Asia, and Australia.

Athyrium's investor base includes public and corporate pension funds, charitable endowments, insurance companies, funds-of-funds, family offices, university endowments, and sovereign wealth funds. The firm's track record includes significant investments in companies such as Basilea Pharmaceutica, Calliditas Therapeutics, Choice Health At Home, Coherus Biosciences, Crown Laboratories, Esperion Therapeutics, and Unlock Health. These investments reflect Athyrium's commitment to supporting innovative healthcare companies and driving value creation in the sector.